Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥124.8bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥180.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥88.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥6.1bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥6.2bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥9.3bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥5.0bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.2bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥2.3bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥1.9bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥137.3bnat 2024-09-30Cons.Assets
Total assets¥117.8bnat 2024-03-31Cons.Assets
Total assets¥107.4bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥79.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥64.9bnat 2024-03-31Cons.Liabilities
Net assets / equity¥58.0bnat 2024-09-30Cons.Net assets
Net assets / equity¥52.8bnat 2024-03-31Cons.Net assets
Net assets / equity¥50.3bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥21.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥27.3bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥21.5bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥26.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.3bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥18.6bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥477m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.4bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥265m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥13.2bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.9bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.2bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥8.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥32.432024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥131.112023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥50.82023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio39.3%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio44.8%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.8%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥686m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2024-04-01 → 2024-09-30¥84.1bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥64m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2024-04-01 → 2024-09-30¥4.2bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2024-04-01 → 2024-09-30¥7.4bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2024-04-01 → 2024-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥622m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2024-04-01 → 2024-09-30¥928m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥33.9bn
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥2.7bn
—segment totalrevenue2024-04-01 → 2024-09-30¥125.5bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥124.8bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥686m
—segment totalsegment profit2024-04-01 → 2024-09-30¥7.9bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥237m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.8bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue external2023-04-01 → 2023-09-30¥81.0bn
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥63m
jpcrp040300-q2r_E03476-000Health Insurance Pharmacyreportable segmentsegment profit2023-04-01 → 2023-09-30¥4.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue external2023-04-01 → 2023-09-30¥6.7bn
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥173m
jpcrp040300-q2r_E03476-000Medical Relatedreportable segmentsegment profit2023-04-01 → 2023-09-30¥801m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥897m
jpcrp040300-q2r_E03476-000Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥142m
—segment totalrevenue2023-04-01 → 2023-09-30¥88.8bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥88.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥237m
—segment totalsegment profit2023-04-01 → 2023-09-30¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 543
ItemContextValueUnit
Net increase decrease in short term loans payable fin cfPrior1YTDDuration7500000000JPY
Net increase decrease in short term loans payable fin cfCurrentYTDDuration-87000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-4493000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-4877000000JPY
Redemption of bonds fin cfPrior1YTDDuration-338000000JPY
Redemption of bonds fin cfCurrentYTDDuration-JPY
Proceeds from disposal of treasury stock fin cfPrior1YTDDuration168000000JPY
Proceeds from disposal of treasury stock fin cfCurrentYTDDuration171000000JPY
Purchase of treasury stock fin cfPrior1YTDDuration-JPY
Purchase of treasury stock fin cfCurrentYTDDuration-0JPY
Additional purchase of investments in consolidated subsidiaries inv cfPrior1YTDDuration-JPY
Additional purchase of investments in consolidated subsidiaries inv cfCurrentYTDDuration-24000000JPY
Cash dividends paid fin cfPrior1YTDDuration-640000000JPY
Cash dividends paid fin cfCurrentYTDDuration-565000000JPY
Dividends paid to non controlling interests fin cfPrior1YTDDuration-JPY
Dividends paid to non controlling interests fin cfCurrentYTDDuration-793000000JPY
Other net fin cfPrior1YTDDuration-25000000JPY
Other net fin cfCurrentYTDDuration-19000000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration2170000000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-6196000000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-1343000000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-5453000000JPY
Cash and cash equivalentsPrior2YearInstant18596000000JPY
Cash and cash equivalentsPrior1YearInstant26944000000JPY
Cash and cash equivalentsPrior1QuarterInstant17253000000JPY
Cash and cash equivalentsCurrentQuarterInstant21490000000JPY
Payroll and allowances sgaPrior1YTDDuration1521000000JPY
Payroll and allowances sgaCurrentYTDDuration2490000000JPY
Provision for bonuses personnel expensesPrior1YTDDuration176000000JPY
Provision for bonuses personnel expensesCurrentYTDDuration145000000JPY
Retirement benefit expenses sgaPrior1YTDDuration32000000JPY
Retirement benefit expenses sgaCurrentYTDDuration52000000JPY
Amortization of goodwill elPrior1YTDDuration1675000000JPY
Amortization of goodwill elCurrentYTDDuration2195000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember80966000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember6675000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember897000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember88540000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember-JPY
Revenues from external customersPrior1YTDDuration88540000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember63000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember173000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember-JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember237000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-237000000JPY
Transactions with other segmentsPrior1YTDDuration-JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E03476-000HealthInsurancePharmacyReportableSegmentsMember81030000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E03476-000MedicalRelatedReportableSegmentMember6849000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E03476-000PharmaceuticalBusinessReportableSegmentMember897000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember88777000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass